（一）本组简介

本组主要负责人为袁权教授，现有教师2名。本组重点发展新冠病毒预防和治疗相关基础应用研究、乙型病毒性肝炎创新诊疗技术和药物、溶瘤病毒和肿瘤靶标，围绕这些目标开展分子病毒学、免疫学、肿瘤学、临床检验诊断学、流行病学和转化医学研究，具体主要包括：

（1） COVID-19疫苗和大分子治疗性药物研究

（2） SARS-CoV-2进化对抗原性及种属嗜性的影响研究

（3） 呼吸道黏膜疫苗与免疫机制

（4） 新型佐剂、VSV病毒载体等疫苗免疫增强技术

（5） 免疫治疗新靶标与抗体药物研发

（6） 针对持续性病毒感染的治疗性抗体与治疗性疫苗研究；

（7） 慢性乙型肝炎治疗应答和转归指导预测诊断新靶标研究；

（8） 模拟人类HBV感染致病的细胞与动物模型研究；

（9） HBV感染及其相关疾病的血清与分子流行病学研究；

（10） 持续性病毒感染与肿瘤的免疫逃逸机制及治疗新技术。

本组近年来累计发表SCI研究论文80余篇；已有4项发明专利获得国内外11件授权，研究成果转化的诊断产品累计10项获得中国NMPA注册证、6项欧盟CE认证，多次获得福建省及厦门市科技进步奖等荣誉。

（二）导师

袁权，博士，教授，博士生导师。Email: yuanquan@xmu.edu.cn

张天英，博士，副教授。Email: zhangtianying@xmu.edu.cn

（三）近年来发表的部分文章

1. Yangtao Wu#; Shaojuan Wang#; Yali Zhang#; Lunzhi Yuan#; Qingbing Zheng#; Min Wei#; Yang Shi#; Zikang Wang; Jian Ma; Kai Wang; Meifeng Nie; Jin Xiao; Zehong Huang; Peiwen Chen; Huilin Guo; Miaolin Lan; Jingjing Xu; Wangheng Hou; Yunda Hong; Dabing Chen; Hui Sun; Hualong Xiong; Ming Zhou; Che Liu; Wenjie Guo; Huiyu Guo; Jiahua Gao; Congling Gan; Zhixiong Li; Haitao Zhang; Xinrui Wang; Shaowei Li; Tong Cheng; Qinjian Zhao; Yixin Chen; Ting Wu; Tianying Zhang*; Jun Zhang*; Hua Cao*; Huachen Zhu*; Quan Yuan*; Yi Guan*; Ningshao Xia*; Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine, Cell Host & Microbe, 2022, 30(12): 1732-1744.e7

2. Wu Y#, Huang X#, Yuan L#, Wang S#, Zhang Y#, Xiong H#, Chen R, Ma J, Qi R, Nie M, Xu J, Zhang Z, Chen L, Wei M, Zhou M, Cai M, Shi Y, Zhang L, Yu H, Hong J, Wang Z, Hong Y, Yue M, Li Z, Chen D, Zheng Q, Li S, Chen Y, Cheng T, Zhang J*, Zhang T*, Zhu H*, Zhao Q*, Yuan Q*, Guan Y*, Xia N*. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci Transl Med. 2021 Aug 11;13(606):eabg1143. (IF: 17.992)

3. Yuan L#, Zhu H#, Zhou M#, Ma J#, Chen R#, Chen Y, Chen L, Wu K, Cai M, Hong J, Li L, Liu C, Yu H, Zhang Y, Wang J, Zhang T, Ge S, Zhang J, Yuan Q, Chen Y, Tang Q, Chen H, Cheng T*, Guan Y*, Xia N*. Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Signal Transduct Target Ther. 2021 Mar 31;6(1):136. (IF: 18.187)

4. Li T#, Xue W#, Zheng Q#, Song S#, Yang C#, Xiong H#, Zhang S, Hong M, Zhang Y, Yu H, Zhang Y, Sun H, Huang Y, Deng T, Chi X, Li J, Wang S, Zhou L, Chen T, Wang Y, Cheng T, Zhang T, Yuan Q, Zhao Q, Zhang J, McLellan JS, Zhou ZH*, Zhang Z*, Li S*, Gu Y*, Xia N*. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nat Commun. 2021 Sep 27;12(1):5652. (IF: 14.919)

5. Yuan L#, Zhu H#, Zhou M#, Ma J#, Chen R#, Yu L, Chen W, Hong W, Wang J, Chen Y, Wu K, Hou W, Zhang Y, Ge S, Chen Y, Yuan Q, Tang Q*, Cheng T*, Guan Y*, Xia N*. Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. Protein Cell. 2022 Jan;13(1):72-77. (IF: 14.87)

6. Yu S#, Yang H#, Li T#, Pan H#, Ren S, Luo G, Jiang J, Yu L, Chen B, Zhang Y, Wang S, Tian R, Zhang T, Zhang S, Chen Y, Yuan Q*, Ge S*, Zhang J*, Xia N*. Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo. Nat Commun. 2021 Aug 26;12(1):5131. (IF: 14.919)

7. Fu W#, Wang W#, Yuan L#, Lin Y, Huang X, Chen R, Cai M, Liu C, Chen L, Zhou M, Wu K, Zhao H, Pan D, Ma J, Hong J, Zhai B, Zhang Y, Kong Z, Wang Y, Chen Y, Yuan Q, Zhu H*, Cheng T*, Guan Y*, Xia N*. A SCID mouse-human lung xenograft model of SARS-CoV-2 infection. Theranostics. 2021 May 3;11(13):6607-6615. (IF: 11.556)

8. Xiong HL#, Cao JL#, Shen CG#, Ma J, Qiao XY, Shi TS, Ge SX, Ye HM, Zhang J, Yuan Q*, Zhang TY*, Xia NS*. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro. Front Pharmacol. 2021 Feb 5;11:609592. (IF: 5.811)

9. Fu S, Zhang J, Yuan Q, Wang Q, Deng Q, Li J, Xia N, Wang Y, Wen Y, Tong S. Lost Small Envelope Protein Expression from Naturally Occurring PreS1 Deletion Mutants of Hepatitis B Virus Is Often Accompanied by Increased HBx and Core Protein Expression as Well as Genome Replication. J Virol. 2021 Jun 24;95(14):e0066021. (IF: 5.101)

10. Zhang J, Wang Y, Fu S, Yuan Q, Wang Q, Xia N, Wen Y, Li J, Tong S. Role of Small Envelope Protein in Sustaining the Intracellular and Extracellular Levels of Hepatitis B Virus Large and Middle Envelope Proteins. Viruses. 2021 Apr 2;13(4):613. (IF: 5.048)

11. Zhang Y#, Wang S#, Wu Y#, Hou W#, Yuan L#, Shen C#, Wang J, Ye J, Zheng Q, Ma J, Xu J, Wei M, Li Z, Nian S, Xiong H, Zhang L, Shi Y, Fu B, Cao J, Yang C, Li Z, Yang T, Liu L, Yu H, Hu J, Ge S, Chen Y, Zhang T, Zhang J, Cheng T*, Yuan Q*, Xia N*. Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods. 2021 Feb 15;5(2):2001031. (IF:12.130)

12. Wang SJ, Chen ZM, Wei M, Liu JQ, Li ZL, Shi TS, Nian S, Fu R, Wu YT, Zhang YL, Wang YB, Zhang TY, Zhang J, Xiong JH, Tong SP, Ge SX, Yuan Q, Xia NS. Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. Emerg Microbes Infect. 2021 Dec;10(1):37-50. (IF: 5.776)

13. Le Chang#, Wangheng Hou#, Lei Zhao#, Yali Zhang#, Yanbin Wang, Linfeng Wu, TingtingXu, Lilin Wang, Juan Wang, Jian Ma, Lan Wang, Junpeng Zhao, Jing Xu, Juan Dong, YingYan, Ru Yang, Yu Li, Fei Guo, Wenjuan Cheng, Yingying Su, Jinfeng Zeng, Wei Han, Tong Cheng, Jun Zhang, Quan Yuan*, Ningshao Xia, Lunan Wang*. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nature communications. 2021;12(1):1383. (IF: 14.919)

14. Zhao J#, Yuan Q#, Wang H#, Liu W#, Liao X#, Su Y#, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. CLINICAL INFECTIOUS DISEASES. 2020;71(16):2027-2034. (IF:8.313)

15. Lu J#, Lu G#, Tan S#, Xia J#, Xiong H#, Yu X, Qi Q, Yu X, Li L, Yu H, Xia N, Zhang T*, Xu Y*, Lin J*. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research. 2020 Oct;30(10):936-939.(IF:20.507)

16. Zhang TY#, Guo XR#, Wu YT#, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020 Feb;69(2):343-354. (IF:19.819)

17. Zhang TY#, Chen HY#, Cao JL#, Xiong HL, Li TL, Kang XZ, Zhao JH, Yin B, Yuan Q*, Xue D*, Xia NS*, Yuan YA. Structural and functional analyses of the Hepatitis B virus X protein BH3-like domain and its interaction with Bcl-xL. Nature Communications. 2019, 10: 3192. (IF: 12.121)

18. Zhang TY†, Guo XR†, Wu YT†, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2019. (IF: 19.819)

19. Yuan L†, Zhang Y†, Liu X†, Chen Y, Zhang L, Cao J, Li X, Wang M, Wu K, Zhang J, Liu G, Tang Q, Yuan Q*, Cheng T*, Xia N*. Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics. 2019; 9(7):2115-2128. (IF: 8.579)

20. Zhang YL†, Gao Y†, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH*, Cheng T, Chen CR*, Yuan Q*, Xia NS. Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerg Microbes Infect. 2019;8(1):724-733. (IF: 5.776)

21. Liu X†, Yuan L†, Zhang L, Mu Y, Li X, Liu C, Lv P, Zhang Y, Cheng T, Yuan Q*, Xia N, Chen X, Liu G*. Bioinspired Artificial Nanodecoys for Hepatitis B Virus. Angewandte chemie-international edition. 2018; 57(38):12499-12503. (IF: 12.959)

22. Zhang JF†, Xiong HL†, Cao JL, Wang SJ, Guo XR, Lin BY, Zhang Y, Zhao JH, Wang YB, Zhang TY*, Yuan Q*, Zhang J, Xia NS. A cell-penetrating whole molecule antibody targeting intracellular HBx suppress hepatitis B virus via TRIM21-dependent pathway, Theranostics.2018, 8(2): 549-562. (IF: 8.579)

23. Zhang TY†, Yuan Q†*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JW, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*, Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2016, 65(4): 658-71. (IF: 19.819)

24. Fan F†, He Z†, Kong LL†, Chen Q†, Yuan Q†, Zhang S, Ye J, Liu H, Sun X, Geng J, Yuan L, Hong L, Xiao C, Zhang W, Sun X, Li Y, Wang P, Huang L, Wu X, Ji Z, Wu Q, Xia NS, Gray NS, Chen L, Yun CH*, Deng X*, Zhou D*. Pharmacological targeting of kinases mst1 and mst2 augments tissue repair and regeneration. Science Translational Medicine, 2016; 8(352), 352ra108. (IF: 16.304)

25. Fan R†, Sun J†, Yuan Q†, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N*, Hou J*. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016, 65(2):313-20. (IF: 19.819)

26. Hou FQ†, Song LW†, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L*, Xia NS*, Wang GQ*. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics. 2015; 5(3):218-26. (IF: 8.579)

27. Song LW†, Wang YB†, Fang LL, Wu Y, Yang L, Chen JY, Ge SX, Zhang J, Xiong YZ, Deng XM, Min XP*, Zhang J, Chen PJ, Yuan Q*, Xia NS. Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping. Anal Chem. 2015;87(10):5173-80. (IF: 6.350)

28. Song LW†, Liu PG†, Liu CJ, Zhang TY, Cheng XD, Wu HL, Yang HC, Hao XK, Yuan Q*, Zhang J, Kao JH, Chen DS, Chen PJ*, Xia NS*. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect. 2015; 21(2):197-203. (IF: 6.452)

（四） 研究成果转化的已上市产品

1.乙型肝炎病毒基因分型检测试剂盒（荧光免疫层析法），国械注准20193400032。

2.乙型肝炎病毒核心抗体测定试剂盒（双抗原夹心化学发光微粒子免疫检测法），国械注准20173401378。

3.乙型肝炎病毒核酸相关抗原检测试剂盒，国食药监械（准）字2010第3400614号。

4乙型肝炎病毒核心抗体双抗原夹心法检测试剂盒，国食药监械（准）字2010第3401232号。

5.乙型肝炎病毒表面抗原检测试剂盒(HBsAg Ultra)，国食药监械（准）字2011第3400140号, CE Marketed, No. 41055/101/1/2012/CE。

6.甲型H1N1流感病毒（2009）HA抗原检测试剂盒，国食药监械（准）字2010第3400974号。

7.甲型流感病毒抗原检测试剂盒，国食药监械（准）字2009第3400979号。

8.丁型肝炎病毒IgG抗体检测试剂，国食药监械（准）字2012第3400893号。

9.丁型肝炎病毒IgM抗体检测试剂，国食药监械（准）字2012第3400895号。

（五）本组优势

研究兴趣广泛，技术平台多样化，与国内外高校、科研院所及生物医药企业合作紧密，学生有较多机会学习到生物医药领域从基础研究到应用转化过程的各个环节中的知识和技术，培养全方位能力。研究小组2009年成立至今，已经毕业博士及硕士研究生近40余人，学生毕业后主要从事科学研究（国内外高校及研究所）、医药及诊断企业、生物医药投研等相关工作。

（六）招生条件

主要对口本科专业：生物学（含生物信息学）、公共卫生与预防医学、临床检验诊断学、药学等，其他专业可邮件咨询。